Eagle Pharmaceuticals, Inc. (EGRX)

Market Cap	9.12M
Revenue (ttm)	257.55M
Net Income (ttm)	11.95M
Shares Out	13.02M
EPS (ttm)	0.91
PE Ratio	0.77
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,800
Open	0.900
Previous Close	0.900
Day's Range	0.750 - 1.000
52-Week Range	0.220 - 9.890
Beta	0.52
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 8, 2024

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2007
• Employees: 134
• Stock Exchange: OTCMKTS
• Ticker Symbol: EGRX